163 related articles for article (PubMed ID: 22554519)
1. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1.
Zhou F; Zhou J; Ma L; Song S; Zhang X; Li W; Jiang S; Wang Y; Liao G
Biochem Biophys Res Commun; 2012 May; 421(4):850-4. PubMed ID: 22554519
[TBL] [Abstract][Full Text] [Related]
2. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
[TBL] [Abstract][Full Text] [Related]
3. A Vero-cell-adapted vaccine donor strain of influenza A virus generated by serial passages.
Hu W; Zhang H; Han Q; Li L; Chen Y; Xia N; Chen Z; Shu Y; Xu K; Sun B
Vaccine; 2015 Jan; 33(2):374-81. PubMed ID: 25448099
[TBL] [Abstract][Full Text] [Related]
4. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
[TBL] [Abstract][Full Text] [Related]
5. Improvement of H5N1 influenza vaccine viruses: influence of internal gene segments of avian and human origin on production and hemagglutinin content.
Abt M; de Jonge J; Laue M; Wolff T
Vaccine; 2011 Jul; 29(32):5153-62. PubMed ID: 21624413
[TBL] [Abstract][Full Text] [Related]
6. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate.
Horimoto T; Takada A; Fujii K; Goto H; Hatta M; Watanabe S; Iwatsuki-Horimoto K; Ito M; Tagawa-Sakai Y; Yamada S; Ito H; Ito T; Imai M; Itamura S; Odagiri T; Tashiro M; Lim W; Guan Y; Peiris M; Kawaoka Y
Vaccine; 2006 Apr; 24(17):3669-76. PubMed ID: 16378663
[TBL] [Abstract][Full Text] [Related]
7. Increase in viral yield in eggs and MDCK cells of reassortant H5N1 vaccine candidate viruses caused by insertion of 38 amino acids into the NA stalk.
Zhang W; Xue T; Wu X; Zhang P; Zhao G; Peng D; Hu S; Wang X; Liu X; Liu W; Liu X
Vaccine; 2011 Oct; 29(45):8032-41. PubMed ID: 21864614
[TBL] [Abstract][Full Text] [Related]
8. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production.
Dong J; Matsuoka Y; Maines TR; Swayne DE; O'Neill E; Davis CT; Van-Hoven N; Balish A; Yu HJ; Katz JM; Klimov A; Cox N; Li DX; Wang Y; Guo YJ; Yang WZ; Donis RO; Shu YL
Influenza Other Respir Viruses; 2009 Nov; 3(6):287-95. PubMed ID: 19903211
[TBL] [Abstract][Full Text] [Related]
9. Long lasting immunity in chickens induced by a single shot of influenza vaccine prepared from inactivated non-pathogenic H5N1 virus particles against challenge with a highly pathogenic avian influenza virus.
Sasaki T; Kokumai N; Ohgitani T; Sakamoto R; Takikawa N; Lin Z; Okamatsu M; Sakoda Y; Kida H
Vaccine; 2009 Aug; 27(38):5174-7. PubMed ID: 19596414
[TBL] [Abstract][Full Text] [Related]
10. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.
Koudstaal W; Hartgroves L; Havenga M; Legastelois I; Ophorst C; Sieuwerts M; Zuijdgeest D; Vogels R; Custers J; de Boer-Luijtze E; de Leeuw O; Cornelissen L; Goudsmit J; Barclay W
Vaccine; 2009 Apr; 27(19):2588-93. PubMed ID: 19428865
[TBL] [Abstract][Full Text] [Related]
11. Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment.
Yu W; Yang F; Yang J; Ma L; Cun Y; Song S; Liao G
J Med Virol; 2016 Nov; 88(11):1914-21. PubMed ID: 27101353
[TBL] [Abstract][Full Text] [Related]
12. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
13. Potency of an inactivated avian influenza vaccine prepared from a non-pathogenic H5N1 reassortant virus generated between isolates from migratory ducks in Asia.
Isoda N; Sakoda Y; Kishida N; Soda K; Sakabe S; Sakamoto R; Imamura T; Sakaguchi M; Sasaki T; Kokumai N; Ohgitani T; Saijo K; Sawata A; Hagiwara J; Lin Z; Kida H
Arch Virol; 2008; 153(9):1685-92. PubMed ID: 18651092
[TBL] [Abstract][Full Text] [Related]
14. [Preparation of vero cell-adapted influenza H5N1 virus strain by genetic reassortment].
Shen J; Sun MB; Ma L; Song SH; Li WD; Jiang SD; Yang JS; Liao GY
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Apr; 24(2):119-21. PubMed ID: 21110431
[TBL] [Abstract][Full Text] [Related]
15. Strategies for developing vaccines against H5N1 influenza A viruses.
Horimoto T; Kawaoka Y
Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
[TBL] [Abstract][Full Text] [Related]
16. Improvement of the H5N1 influenza virus vaccine strain to decrease the pathogenicity in chicken embryos.
Isoda N; Sakoda Y; Okamatsu M; Tsuda Y; Kida H
Arch Virol; 2011 Apr; 156(4):557-63. PubMed ID: 21203786
[TBL] [Abstract][Full Text] [Related]
17. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
[TBL] [Abstract][Full Text] [Related]
18. Single dose of oil-adjuvanted inactivated vaccine protects chickens from lethal infections of highly pathogenic H5N1 influenza virus.
Hwang SD; Kim HS; Cho SW; Seo SH
Vaccine; 2011 Mar; 29(11):2178-86. PubMed ID: 21172378
[TBL] [Abstract][Full Text] [Related]
19. Effect of gene constellation and postreassortment amino acid change on the phenotypic features of H5 influenza virus reassortants.
Rudneva IA; Timofeeva TA; Shilov AA; Kochergin-Nikitsky KS; Varich NL; Ilyushina NA; Gambaryan AS; Krylov PS; Kaverin NV
Arch Virol; 2007; 152(6):1139-45. PubMed ID: 17294090
[TBL] [Abstract][Full Text] [Related]
20. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.
Hu AY; Weng TC; Tseng YF; Chen YS; Wu CH; Hsiao S; Chou AH; Chao HJ; Gu A; Wu SC; Chong P; Lee MS
Vaccine; 2008 Oct; 26(45):5736-40. PubMed ID: 18761387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
